GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ANI Pharmaceuticals Inc (NAS:ANIP) » Definitions » Beneish M-Score
中文

ANI Pharmaceuticals (ANI Pharmaceuticals) Beneish M-Score : -2.94 (As of Apr. 24, 2024)


View and export this data going back to 1999. Start your Free Trial

What is ANI Pharmaceuticals Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.94 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for ANI Pharmaceuticals's Beneish M-Score or its related term are showing as below:

ANIP' s Beneish M-Score Range Over the Past 10 Years
Min: -3.27   Med: -2.55   Max: -1.26
Current: -2.94

During the past 13 years, the highest Beneish M-Score of ANI Pharmaceuticals was -1.26. The lowest was -3.27. And the median was -2.55.


ANI Pharmaceuticals Beneish M-Score Historical Data

The historical data trend for ANI Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ANI Pharmaceuticals Beneish M-Score Chart

ANI Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.90 -2.46 -2.33 -2.31 -2.94

ANI Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.31 -2.43 -2.54 -2.56 -2.94

Competitive Comparison of ANI Pharmaceuticals's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, ANI Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ANI Pharmaceuticals's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ANI Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where ANI Pharmaceuticals's Beneish M-Score falls into.



ANI Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of ANI Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.6367+0.528 * 0.8951+0.404 * 0.767+0.892 * 1.5387+0.115 * 1.0121
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8472+4.679 * -0.107763-0.327 * 0.939
=-2.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $162.1 Mil.
Revenue was 131.654 + 131.829 + 116.547 + 106.786 = $486.8 Mil.
Gross Profit was 78.234 + 83.728 + 74.263 + 69.078 = $305.3 Mil.
Total Current Assets was $519.8 Mil.
Total Assets was $904.4 Mil.
Property, Plant and Equipment(Net PPE) was $44.6 Mil.
Depreciation, Depletion and Amortization(DDA) was $59.8 Mil.
Selling, General, & Admin. Expense(SGA) was $161.7 Mil.
Total Current Liabilities was $145.5 Mil.
Long-Term Debt & Capital Lease Obligation was $284.8 Mil.
Net Income was 1.155 + 9.94 + 6.245 + 1.439 = $18.8 Mil.
Non Operating Income was -2.018 + 2.516 + -1.09 + -2.125 = $-2.7 Mil.
Cash Flow from Operations was 44.74 + 32.169 + 20.626 + 21.424 = $119.0 Mil.
Total Receivables was $165.4 Mil.
Revenue was 94.232 + 83.821 + 73.855 + 64.477 = $316.4 Mil.
Gross Profit was 57.906 + 50.927 + 38.561 + 30.206 = $177.6 Mil.
Total Current Assets was $344.3 Mil.
Total Assets was $760.1 Mil.
Property, Plant and Equipment(Net PPE) was $43.2 Mil.
Depreciation, Depletion and Amortization(DDA) was $59.7 Mil.
Selling, General, & Admin. Expense(SGA) was $124.0 Mil.
Total Current Liabilities was $99.4 Mil.
Long-Term Debt & Capital Lease Obligation was $285.7 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(162.079 / 486.816) / (165.438 / 316.385)
=0.332937 / 0.522901
=0.6367

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(177.6 / 316.385) / (305.303 / 486.816)
=0.561341 / 0.627142
=0.8951

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (519.816 + 44.593) / 904.422) / (1 - (344.261 + 43.246) / 760.087)
=0.375945 / 0.490181
=0.767

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=486.816 / 316.385
=1.5387

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(59.653 / (59.653 + 43.246)) / (59.791 / (59.791 + 44.593))
=0.579724 / 0.572799
=1.0121

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(161.697 / 486.816) / (124.044 / 316.385)
=0.332152 / 0.392067
=0.8472

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((284.819 + 145.477) / 904.422) / ((285.669 + 99.439) / 760.087)
=0.475769 / 0.506663
=0.939

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(18.779 - -2.717 - 118.959) / 904.422
=-0.107763

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

ANI Pharmaceuticals has a M-score of -2.94 suggests that the company is unlikely to be a manipulator.


ANI Pharmaceuticals Beneish M-Score Related Terms

Thank you for viewing the detailed overview of ANI Pharmaceuticals's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


ANI Pharmaceuticals (ANI Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
210 Main Street West, Baudette, MN, USA, 56623
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Executives
Muthusamy Shanmugam director, officer: HEAD OF R&D, COO-NOVITIUM OPS C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Meredith Cook officer: SR. VP, GENERAL COUNSEL & SEC. C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Krista Davis officer: SVP, CHIEF HR OFFICER C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Christopher Mutz officer: HEAD OF RARE DISEASE C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Chad Gassert officer: SVP - CORP. DEV. & STRATEGY C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Ori Gutwerg officer: SVP, GENERICS C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
James G. Marken officer: Vice President, Operations 210 MAIN STREET WEST, C/O BIOSANTE PHARMACEUTICALS, INC., BAUDETTE MN 56623
Matthew J Leonard director 7 CUSTOM HOUSE STREET, PORTLAND ME 04101
Meridian Venture Partners Ii Lp 10 percent owner
Nikhil Lalwani director, officer: PRESIDENT & CEO C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET, BAUDETTE MN 56623
Antonio R Pera director C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET, BAUDETTE MN 56623
Stephen P. Carey officer: Vice President and CFO C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Renee P Tannenbaum director 9220 KIRBY DRIVE, SUITE 500, HOUSTON TX 77054
Jeanne Thoma director C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Patrick D Walsh director 14282 FRANKLIN AVE., TUSTIN CA 92780